{
    "hands_on_practices": [
        {
            "introduction": "The hallmark of Minimal Change Disease is highly \"selective\" proteinuria, a concept that can be precisely quantified. This exercise challenges you to calculate the proteinuria selectivity index, a powerful diagnostic tool derived from the relative renal clearances of small (albumin) and large (IgG) proteins. Mastering this calculation provides a direct, quantitative link to the underlying pathophysiology of a compromised glomerular charge barrier and helps differentiate MCD from conditions causing non-selective proteinuria. ",
            "id": "4407820",
            "problem": "A child presents with edema and heavy proteinuria. You are given simultaneous measurements from a timed urine collection and a venous blood sample. Serum albumin is $25{,}000$ mg/L, serum Immunoglobulin G (IgG) is $12{,}000$ mg/L, urine albumin concentration is $2{,}000$ mg/L, and urine IgG concentration is $20$ mg/L. Assume that the urine flow rate during the collection is the same for both proteins and the samples are paired. Starting from the definition of renal clearance and the concept of proteinuria selectivity used in clinical nephrology, derive an expression for the selectivity index as a ratio of clearances and compute its value from the provided data. Round your final numeric answer to three significant figures and express it as a dimensionless number. Based on the magnitude of the computed selectivity index, explain whether the proteinuria pattern supports a diagnosis of minimal change disease.",
            "solution": "The problem asks for the derivation and calculation of the proteinuria selectivity index from provided clinical data, and an interpretation of the result in the context of minimal change disease.\n\nFirst, we must establish the theoretical framework. The renal clearance ($C_X$) of a substance $X$ is defined as the volume of plasma from which the substance is completely removed by the kidneys per unit time. Mathematically, it is expressed as:\n$$\nC_X = \\frac{U_X \\cdot V}{P_X}\n$$\nwhere $U_X$ is the concentration of the substance in urine, $P_X$ is its concentration in plasma (or serum, for substances not present in red blood cells), and $V$ is the urine flow rate.\n\nThe problem requires us to evaluate the selectivity of proteinuria. The selectivity index ($SI$) is a dimensionless parameter used to quantify the degree to which the damaged glomerulus discriminates between proteins of different molecular sizes. It is typically defined as the ratio of the clearance of a high-molecular-weight protein to that of a lower-molecular-weight protein. In this case, we use Immunoglobulin G (IgG, a large protein with molecular weight $\\approx 150$ kDa) and albumin (a smaller protein with molecular weight $\\approx 66.5$ kDa).\n\nThe selectivity index is therefore given by the ratio of the clearance of IgG to the clearance of albumin:\n$$\nSI = \\frac{C_{IgG}}{C_{alb}}\n$$\n\nWe can substitute the general clearance formula for each protein.\nFor IgG, the clearance is:\n$$\nC_{IgG} = \\frac{U_{IgG} \\cdot V}{P_{IgG}}\n$$\nFor albumin, the clearance is:\n$$\nC_{alb} = \\frac{U_{alb} \\cdot V}{P_{alb}}\n$$\nHere, $U_{IgG}$ and $U_{alb}$ are the urine concentrations of IgG and albumin, respectively. $P_{IgG}$ and $P_{alb}$ are the serum concentrations of IgG and albumin, respectively. The urine flow rate, $V$, is the same for both measurements as they are taken from the same timed collection.\n\nSubstituting these expressions into the equation for the selectivity index, we get:\n$$\nSI = \\frac{\\left( \\frac{U_{IgG} \\cdot V}{P_{IgG}} \\right)}{\\left( \\frac{U_{alb} \\cdot V}{P_{alb}} \\right)}\n$$\nThe urine flow rate $V$ is a common factor in the numerator and the denominator, so it cancels out:\n$$\nSI = \\frac{U_{IgG} / P_{IgG}}{U_{alb} / P_{alb}}\n$$\nRearranging this complex fraction, we arrive at the final expression for the selectivity index:\n$$\nSI = \\frac{U_{IgG} \\cdot P_{alb}}{P_{IgG} \\cdot U_{alb}}\n$$\nThis expression allows the calculation of the selectivity index using only the concentrations of the two proteins in paired urine and serum samples, without needing to measure the urine flow rate.\n\nNow, we can compute the value of the selectivity index using the data provided in the problem statement:\n-   Serum albumin concentration, $P_{alb} = 25{,}000$ mg/L\n-   Serum IgG concentration, $P_{IgG} = 12{,}000$ mg/L\n-   Urine albumin concentration, $U_{alb} = 2{,}000$ mg/L\n-   Urine IgG concentration, $U_{IgG} = 20$ mg/L\n\nSubstituting these values into our derived formula:\n$$\nSI = \\frac{(20 \\text{ mg/L}) \\cdot (25{,}000 \\text{ mg/L})}{(12{,}000 \\text{ mg/L}) \\cdot (2{,}000 \\text{ mg/L})}\n$$\nThe units of mg/L in the numerator and denominator cancel out, rendering the index dimensionless, as required.\n$$\nSI = \\frac{20 \\cdot 25{,}000}{12{,}000 \\cdot 2{,}000} = \\frac{500{,}000}{24{,}000{,}000} = \\frac{5}{240} = \\frac{1}{48}\n$$\nConverting this fraction to a decimal gives:\n$$\nSI = 0.0208333...\n$$\nRounding the result to three significant figures, as requested, yields:\n$$\nSI \\approx 0.0208\n$$\n\nFinally, we must interpret this result. A low selectivity index indicates \"selective proteinuria,\" where the glomerular filtration barrier preferentially leaks smaller proteins (like albumin) while largely retaining larger proteins (like IgG). A high selectivity index signifies \"non-selective proteinuria,\" indicating more severe glomerular damage that allows proteins of various sizes to pass into the urine.\n\nClinically, a selectivity index less than $0.2$ is generally considered indicative of highly selective proteinuria. Our calculated value of $SI \\approx 0.0208$ is well below this threshold.\n\nThis finding has direct diagnostic implications. Minimal change disease (MCD) is a podocytopathy, a disease affecting the podocytes of the glomerulus. The primary pathology is the widespread effacement (flattening) of podocyte foot processes, which leads to a loss of the normal charge-selective barrier of the glomerulus. This allows the negatively charged, relatively small albumin molecule to pass through in large quantities, causing heavy proteinuria and nephrotic syndrome. However, the larger structural integrity of the glomerular basement membrane is largely preserved, so the filtration of larger molecules like IgG is only minimally increased. Consequently, minimal change disease is the archetypal cause of highly selective proteinuria.\n\nIn contrast, other causes of nephrotic syndrome, such as focal segmental glomerulosclerosis (FSGS) or membranous nephropathy, involve more extensive structural damage to the glomerular filtration barrier, resulting in larger \"pores\" and leading to non-selective proteinuria (typically with $SI > 0.2$ or $0.3$).\n\nTherefore, the calculated selectivity index of $0.0208$ indicates highly selective proteinuria, a pattern that is characteristic of and strongly supports a diagnosis of minimal change disease in this child.",
            "answer": "$$\n\\boxed{0.0208}\n$$"
        },
        {
            "introduction": "Arriving at a definitive diagnosis of Minimal Change Disease requires a systematic approach that distinguishes it from other causes of nephrotic syndrome. This practice asks you to construct a logical diagnostic pathway to differentiate MCD from primary Membranous Nephropathy, a key mimic. By integrating modern serological testing with classic renal biopsy findings, you will develop the clinical reasoning skills needed to navigate the diagnostic process from initial presentation to final classification. ",
            "id": "4407813",
            "problem": "A $32$-year-old patient presents with edema and nephrotic-range proteinuria confirmed on timed urine collection. Renal function is preserved, and serum complement levels are within normal limits. You are tasked with constructing a decision pathway that distinguishes Minimal Change Disease (MCD) from primary Membranous Nephropathy (MN) using non-invasive serologies and, if needed, renal biopsy interpreted by immunofluorescence (IF) and electron microscopy (EM). Your algorithm must be grounded in the following fundamental principles: the glomerular filtration barrier consists of fenestrated endothelium, glomerular basement membrane (GBM), and podocyte slit diaphragm; immune complex formation requires antigen-antibody binding governed by specificity and affinity; immune complexes localize within the glomerulus according to size and charge and produce characteristic IF patterns; and podocyte injury without immune complex deposition produces foot process effacement and proteinuria due to increased permeability to albumin.\n\nDefinitions for acronyms used: immunofluorescence (IF), electron microscopy (EM), phospholipase A$2$ receptor ($PLA2R$), thrombospondin type-$1$ domain-containing $7A$ ($THSD7A$), immunoglobulin G ($IgG$), immunoglobulin M ($IgM$), complement component $3$ ($C3$), glomerular basement membrane (GBM), anti-nuclear antibody (ANA), double-stranded deoxyribonucleic acid (dsDNA), anti-glomerular basement membrane (anti-GBM).\n\nWhich of the following algorithms most defensibly discriminates MCD from primary MN using serologies, IF, and EM, and is consistent with the stated first principles?\n\nA. Begin with serum $PLA2R$ and $THSD7A$ autoantibodies. If either is positive, classify as MN. If both are negative, proceed to kidney biopsy. On IF, absence of capillary wall granular $IgG$/$C3$ (with at most mild mesangial $IgM$/$C3$ trapping) favors MCD; on EM, diffuse podocyte foot process effacement without electron-dense deposits confirms MCD. Conversely, IF showing granular capillary wall $IgG$ and $C3$ with EM demonstrating subepithelial electron-dense deposits supports MN.\n\nB. Start with serum complement. If complement is low, diagnose MN; if complement is normal, diagnose MCD. Biopsy is unnecessary because complement status alone discriminates these diseases.\n\nC. Proceed directly to IF on biopsy. A linear $IgG$ pattern along the GBM indicates MN, whereas a granular $IgG$ pattern indicates MCD. EM should be reserved only if IF is inconclusive because immune complexes are best seen by IF.\n\nD. Initiate high-dose corticosteroids and classify based on clinical response: rapid remission within two weeks indicates MCD; failure to remit indicates MN. Use EM afterwards only to document foot process effacement as the final confirmatory step.\n\nE. Screen for ANA and anti-dsDNA. If either is positive, diagnose MN; if negative, diagnose MCD. If biopsy is performed, the presence of foot process effacement on EM is sufficient to confirm MCD regardless of IF findings.",
            "solution": "The problem statement is a valid exercise in clinical pathological reasoning, presenting a classic differential diagnosis in nephrology. It is scientifically grounded, well-posed, and objective. We begin by validating the problem as per the required protocol.\n\n### Step 1: Extract Givens\n- **Patient Profile**: $32$-year-old patient.\n- **Clinical Presentation**: Edema and nephrotic-range proteinuria.\n- **Laboratory Data**: Preserved renal function, serum complement levels within normal limits.\n- **Objective**: To construct a decision pathway distinguishing Minimal Change Disease (MCD) from primary Membranous Nephropathy (MN).\n- **Available Tools**: Non-invasive serologies, renal biopsy with immunofluorescence (IF) and electron microscopy (EM).\n- **Stated Principles**:\n    1.  The glomerular filtration barrier comprises fenestrated endothelium, glomerular basement membrane (GBM), and podocyte slit diaphragm.\n    2.  Immune complex formation is governed by antigen-antibody specificity and affinity.\n    3.  Immune complexes localize based on size and charge, yielding characteristic IF patterns.\n    4.  Podocyte injury without immune complex deposition causes foot process effacement and proteinuria.\n- **Acronym Definitions**: immunofluorescence (IF), electron microscopy (EM), phospholipase A$2$ receptor ($PLA2R$), thrombospondin type-$1$ domain-containing $7A$ ($THSD7A$), immunoglobulin G ($IgG$), immunoglobulin M ($IgM$), complement component $3$ ($C3$), glomerular basement membrane (GBM), anti-nuclear antibody (ANA), double-stranded deoxyribonucleic acid (dsDNA), anti-glomerular basement membrane (anti-GBM).\n\n### Step 2: Validate Using Extracted Givens\nThe problem is **valid**.\n- **Scientifically Grounded**: The scenario describes nephrotic syndrome in an adult, a common clinical problem. The distinction between MCD and primary MN is a central topic in nephropathology. The described pathophysiological principles are correct: MN is an immune-complex-mediated disease characterized by autoantibodies against podocyte antigens (principle 2), leading to subepithelial deposits and a granular IF pattern (principle 3). MCD is a podocytopathy characterized by foot process effacement without immune deposits (principle 4), leading to proteinuria by compromising the slit diaphragm (part of principle 1). The diagnostic tools ($anti-PLA2R$ antibodies, biopsy with IF/EM) are the standard of care.\n- **Well-Posed**: The question asks for the most defensible algorithm among a set of choices, based on provided principles. This is a clear and answerable task.\n- **Objective**: The problem uses standard, precise medical terminology and is free of subjective or ambiguous language.\n\n### Derivation of the Correct Diagnostic Algorithm\nBased on the provided principles and established medical knowledge, the optimal algorithm to distinguish primary MN from MCD in an adult with nephrotic syndrome and normal complement is as follows:\n\n1.  **Initial Non-invasive Step (Serology)**: Primary MN is an autoimmune disease, most commonly (>70%) caused by autoantibodies targeting the phospholipase A$2$ receptor ($PLA2R$), an antigen on the podocyte surface. A smaller fraction of cases involve antibodies against thrombospondin type-$1$ domain-containing $7$A ($THSD7A$). Therefore, testing for serum anti-$PLA2R$ and anti-$THSD7A$ antibodies is the logical first step. A positive result is highly specific for primary MN, potentially obviating the need for a biopsy. MCD is not associated with these autoantibodies.\n\n2.  **Contingent Invasive Step (Biopsy)**: If serologies are negative, a definitive diagnosis cannot be made, and a renal biopsy is necessary. This is because a subset of primary MN is seronegative, and other causes of nephrotic syndrome (like FSGS or secondary forms of MN) must be excluded.\n\n3.  **Biopsy Interpretation**:\n    - **Immunofluorescence (IF)**:\n        - In **MN**, the *in situ* formation of immune complexes on the outer aspect of the GBM (subepithelial space) results in a characteristic diffuse, fine-to-coarse **granular** staining pattern for $IgG$ (typically $IgG4$ subclass) and $C3$ along the glomerular capillary walls. This is a direct consequence of principle 3.\n        - In **MCD**, there are by definition no primary immune deposits. Therefore, IF is classically **negative** for immunoglobulins and complement. Occasionally, minor, non-specific mesangial \"trapping\" of $IgM$ and/or $C3$ may be observed, but this lacks the organized, capillary wall pattern seen in immune-complex diseases.\n    - **Electron Microscopy (EM)**:\n        - In **MN**, EM provides definitive confirmation by revealing electron-dense deposits located in the **subepithelial** space, between the podocyte and the GBM. Podocyte foot process effacement is also present but is a secondary finding.\n        - In **MCD**, EM is the gold standard for diagnosis. It demonstrates diffuse, widespread (typically >80%) effacement of podocyte foot processes in the **absence** of any electron-dense immune deposits. This directly reflects principle 4.\n\nThis derived algorithm represents the current standard of care and is fully consistent with the provided pathophysiological principles.\n\n### Evaluation of Options\n\n- **A. Begin with serum $PLA2R$ and $THSD7A$ autoantibodies. If either is positive, classify as MN. If both are negative, proceed to kidney biopsy. On IF, absence of capillary wall granular $IgG$/$C3$ (with at most mild mesangial $IgM$/$C3$ trapping) favors MCD; on EM, diffuse podocyte foot process effacement without electron-dense deposits confirms MCD. Conversely, IF showing granular capillary wall $IgG$ and $C3$ with EM demonstrating subepithelial electron-dense deposits supports MN.**\nThis option precisely matches the correct diagnostic algorithm derived from first principles. It correctly prioritizes non-invasive, highly specific serologies. It correctly describes the indication for biopsy. It accurately characterizes the pathognomonic IF and EM findings for both MCD (negative IF, effacement on EM without deposits) and MN (granular $IgG$/$C3$ on IF, subepithelial deposits on EM). The nuanced mention of possible mild mesangial trapping in MCD is also correct.\n**Verdict: Correct**\n\n- **B. Start with serum complement. If complement is low, diagnose MN; if complement is normal, diagnose MCD. Biopsy is unnecessary because complement status alone discriminates these diseases.**\nThis option is fundamentally incorrect. The problem statement itself indicates serum complement is *normal*. Furthermore, both primary MN and MCD are typically associated with normal serum complement levels. Low complement would suggest a secondary cause, such as lupus nephritis, not primary MN. Therefore, complement status is not a useful discriminator between these two specific entities.\n**Verdict: Incorrect**\n\n- **C. Proceed directly to IF on biopsy. A linear $IgG$ pattern along the GBM indicates MN, whereas a granular $IgG$ pattern indicates MCD. EM should be reserved only if IF is inconclusive because immune complexes are best seen by IF.**\nThis option contains multiple, critical errors. First, a **linear** $IgG$ pattern is the hallmark of anti-GBM disease, not MN. MN is characterized by a **granular** pattern. Second, it incorrectly attributes a granular pattern to MCD, which is defined by the *absence* of such deposits. Third, it devalues the role of EM. EM is not a secondary tool; it is essential for visualizing the ultrastructural location of deposits in MN and for confirming the absence of deposits in MCD, which is the definitive finding.\n**Verdict: Incorrect**\n\n- **D. Initiate high-dose corticosteroids and classify based on clinical response: rapid remission within two weeks indicates MCD; failure to remit indicates MN. Use EM afterwards only to document foot process effacement as the final confirmatory step.**\nThis describes trial-by-therapy, which is not the standard of care for adults with undiagnosed nephrotic syndrome. While children are often treated empirically for MCD, the differential diagnosis in adults is broader, and treatment for MN differs significantly from that for MCD. Making a diagnosis based on response is imprecise and can lead to inappropriate treatment and delays. A biopsy is required *before* initiating potent, long-term therapy to establish a definitive diagnosis.\n**Verdict: Incorrect**\n\n- **E. Screen for ANA and anti-dsDNA. If either is positive, diagnose MN; if negative, diagnose MCD. If biopsy is performed, the presence of foot process effacement on EM is sufficient to confirm MCD regardless of IF findings.**\nThis option is flawed. ANA and anti-dsDNA are markers for systemic lupus erythematosus. A positive result would suggest lupus nephritis (a *secondary* cause of a membranous pattern), not primary MN. A negative result does not rule out primary MN nor does it confirm MCD. The second sentence contains a grave error: foot process effacement is a non-specific finding in proteinuric states and is seen in both MCD and MN. The defining feature of MCD is the *combination* of effacement and the *absence* of immune deposits, a fact that cannot be established without correlating EM and IF findings.\n**Verdict: Incorrect**",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "Translating a diagnosis into effective treatment is a critical skill, and in Minimal Change Disease, this often involves corticosteroid therapy tailored to the patient. This problem puts you in the clinician's shoes, tasking you with calculating and comparing cumulative prednisone doses for pediatric and adult patients based on standard, weight-based regimens. This practical application highlights how treatment protocols are quantitatively adjusted for different populations to maximize efficacy while managing drug exposure. ",
            "id": "4407735",
            "problem": "A child with Minimal Change Disease (MCD) is being treated with prednisone. Minimal Change Disease (MCD) is a common cause of nephrotic syndrome characterized by podocyte foot process effacement and steroid responsiveness. For dosing in MCD, widely used clinical guidance (such as that recommended by Kidney Disease: Improving Global Outcomes (KDIGO)) uses weight-based prednisone regimens with daily dosing followed by an alternate-day phase in children, and weight-based daily dosing with tapering in adults.\n\nConsider the following scientifically plausible regimens over a fixed horizon of eight weeks, where each week is assumed to contain $7$ consecutive days. The child weighs $20\\,\\mathrm{kg}$ and the adult weighs $70\\,\\mathrm{kg}$. The maximum permitted initial daily dose caps are $60\\,\\mathrm{mg/day}$ for children and $80\\,\\mathrm{mg/day}$ for adults.\n\nChild regimen:\n- Weeks $1$–$5$: daily prednisone at $2\\,\\mathrm{mg/kg/day}$.\n- Weeks $6$–$8$: prednisone at $1.5\\,\\mathrm{mg/kg}$ on alternate days, starting with a dose on the first day of week $6$ (i.e., dosing on days $1,3,5,\\ldots$ of the $21$-day period).\n\nAdult regimen:\n- Weeks $1$–$6$: daily prednisone at $1\\,\\mathrm{mg/kg/day}$.\n- Weeks $7$–$8$: daily prednisone at $0.5\\,\\mathrm{mg/kg/day}$.\n\nAssume no dose adjustments other than the stated caps, and no missed doses. Using the definition of weight-based dosing (milligrams per kilogram per day), compute the cumulative prednisone exposure in milligrams for the child over $8$ weeks and for the adult over $8$ weeks. Then compute the ratio of cumulative exposure (child divided by adult). Express the final ratio as a decimal rounded to four significant figures. Do not include units in your final answer.",
            "solution": "The problem is valid. It is scientifically grounded in established clinical pharmacology for Minimal Change Disease, well-posed with all necessary data provided, and objective in its phrasing. All conditions are internally consistent and allow for the calculation of a unique, meaningful solution.\n\nThe problem requires the calculation of the cumulative prednisone exposure for both a child and an adult over an $8$-week period and then computing the ratio of these exposures. The total duration of the treatment horizon is $8 \\text{ weeks} \\times 7 \\text{ days/week} = 56$ days.\n\nLet $E_c$ be the cumulative exposure for the child and $E_a$ be the cumulative exposure for the adult.\n\n**1. Calculation of Child's Cumulative Exposure ($E_c$)**\n\nThe child's weight is given as $w_c = 20\\,\\mathrm{kg}$. The maximum daily dose cap is $C_c = 60\\,\\mathrm{mg/day}$. The regimen is split into two phases.\n\n*   **Phase 1: Weeks $1$–$5$ (Duration $T_{c,1} = 5 \\times 7 = 35$ days)**\n    The prescribed daily dose rate is $D_{c,1} = 2\\,\\mathrm{mg/kg/day}$.\n    The calculated daily dose is:\n    $$d_{c,1} = D_{c,1} \\times w_c = (2\\,\\mathrm{mg/kg/day}) \\times (20\\,\\mathrm{kg}) = 40\\,\\mathrm{mg/day}$$\n    This dose must be compared to the maximum daily cap: $40\\,\\mathrm{mg/day} \\le 60\\,\\mathrm{mg/day}$. The calculated dose does not exceed the cap.\n    The cumulative exposure for this phase is:\n    $$E_{c,1} = d_{c,1} \\times T_{c,1} = (40\\,\\mathrm{mg/day}) \\times (35\\,\\mathrm{days}) = 1400\\,\\mathrm{mg}$$\n\n*   **Phase 2: Weeks $6$–$8$ (Duration $T_{c,2} = 3 \\times 7 = 21$ days)**\n    The regimen is prednisone at $1.5\\,\\mathrm{mg/kg}$ on alternate days, starting on the first day of this phase.\n    The dose amount per administration is:\n    $$A_{c,2} = (1.5\\,\\mathrm{mg/kg}) \\times (20\\,\\mathrm{kg}) = 30\\,\\mathrm{mg}$$\n    This amount, administered on a given day, is less than the daily cap of $60\\,\\mathrm{mg}$, so no adjustment is needed.\n    The dosing occurs on days $1, 3, 5, \\ldots$ of the $21$-day period. The number of dosing days, $N_{c,doses}$, is the number of odd integers in the interval $[1, 21]$. This is given by $\\lceil \\frac{21}{2} \\rceil = \\lceil 10.5 \\rceil = 11$ days.\n    The cumulative exposure for this phase is:\n    $$E_{c,2} = A_{c,2} \\times N_{c,doses} = (30\\,\\mathrm{mg}) \\times 11 = 330\\,\\mathrm{mg}$$\n\n*   **Total Child Exposure ($E_c$)**\n    The total cumulative exposure for the child is the sum of the exposures from both phases:\n    $$E_c = E_{c,1} + E_{c,2} = 1400\\,\\mathrm{mg} + 330\\,\\mathrm{mg} = 1730\\,\\mathrm{mg}$$\n\n**2. Calculation of Adult's Cumulative Exposure ($E_a$)**\n\nThe adult's weight is given as $w_a = 70\\,\\mathrm{kg}$. The maximum daily dose cap is $C_a = 80\\,\\mathrm{mg/day}$. The regimen is split into two phases.\n\n*   **Phase 1: Weeks $1$–$6$ (Duration $T_{a,1} = 6 \\times 7 = 42$ days)**\n    The prescribed daily dose rate is $D_{a,1} = 1\\,\\mathrm{mg/kg/day}$.\n    The calculated daily dose is:\n    $$d_{a,1} = D_{a,1} \\times w_a = (1\\,\\mathrm{mg/kg/day}) \\times (70\\,\\mathrm{kg}) = 70\\,\\mathrm{mg/day}$$\n    This dose is less than the cap: $70\\,\\mathrm{mg/day} \\le 80\\,\\mathrm{mg/day}$. The dose is not capped.\n    The cumulative exposure for this phase is:\n    $$E_{a,1} = d_{a,1} \\times T_{a,1} = (70\\,\\mathrm{mg/day}) \\times (42\\,\\mathrm{days}) = 2940\\,\\mathrm{mg}$$\n\n*   **Phase 2: Weeks $7$–$8$ (Duration $T_{a,2} = 2 \\times 7 = 14$ days)**\n    The prescribed daily dose rate is $D_{a,2} = 0.5\\,\\mathrm{mg/kg/day}$.\n    The calculated daily dose is:\n    $$d_{a,2} = D_{a,2} \\times w_a = (0.5\\,\\mathrm{mg/kg/day}) \\times (70\\,\\mathrm{kg}) = 35\\,\\mathrm{mg/day}$$\n    This dose is well below the cap of $80\\,\\mathrm{mg/day}$.\n    The cumulative exposure for this phase is:\n    $$E_{a,2} = d_{a,2} \\times T_{a,2} = (35\\,\\mathrm{mg/day}) \\times (14\\,\\mathrm{days}) = 490\\,\\mathrm{mg}$$\n\n*   **Total Adult Exposure ($E_a$)**\n    The total cumulative exposure for the adult is the sum of the exposures from both phases:\n    $$E_a = E_{a,1} + E_{a,2} = 2940\\,\\mathrm{mg} + 490\\,\\mathrm{mg} = 3430\\,\\mathrm{mg}$$\n\n**3. Calculation of the Ratio**\n\nThe final step is to compute the ratio of the child's cumulative exposure to the adult's cumulative exposure, $R = E_c / E_a$.\n$$R = \\frac{E_c}{E_a} = \\frac{1730}{3430} = \\frac{173}{343}$$\nTo express this as a decimal rounded to four significant figures:\n$$R \\approx 0.5043731778\\ldots$$\nRounding to four significant figures gives $0.5044$.",
            "answer": "$$\\boxed{0.5044}$$"
        }
    ]
}